deTorres AT, et al. - In this trial, audiometric natural progression in patient-ears with small volume (<1,000 mm³), treatment-naive cochleovestibular schwannomas (CVSs) in neurofibromatosis Type 2 (NF2) were characterized. A low annual hearing decrease rate (AHDR) and low risk of significant hearing loss were noted in the patients with normal baseline hearing and small internal auditory canal (IAC) tumor component. These patients might require conservative management; however, the presence of baseline hearing loss and large IAC volume were observed to be associated with higher ADHR and increased risk for further hearing loss and could benefit from early treatment interventions.